INTACT SIGNED
Imaging NM: A Nanoparticulate Precision Medicine Approach to Target Cancer
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0INTACT project word cloud
Explore the words cloud of the INTACT project. It provides you a very rough idea of what is the project "INTACT" about.
Project "INTACT" data sheet
The following table provides information about the project.
| Coordinator |
CRISTAL DELIVERY BV
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Project website | http://www.cristaltherapeutics.com |
| Total cost | 8˙996˙610 € |
| EC max contribution | 2˙499˙999 € (28%) |
| Programme |
1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) |
| Code Call | H2020-SMEINST-2-2016-2017 |
| Funding Scheme | SME-2 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-08-01 to 2019-07-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | CRISTAL DELIVERY BV | NL (MAASTRICHT) | coordinator | 2˙499˙999.00 |
Map
Project objective
Cristal Therapeutics (CT) develops the next generation of nanomedicines to treat cancer. Cancer remains one the leading causes of death worldwide, and current treatment options are insufficient, in part due to the tumour heterogeneity between patients. CT has developed state-of-the-art nanoparticles (CriPec®) to target a drug of choice more selectively to the tumour site(s). The superior therapeutic performance of this approach has already been demonstrated preclinically for CT’ lead product CriPec® docetaxel and a promising clinical phase I trial is finalizing, providing a significantly increased pharmacokinetic and safety profile. CT already observed activity in patients and much reduced neutropenia and alopecia. In INTACT, CT will perform phase II clinical trials in ovarian and bladder cancer to evaluate the therapeutic efficacy of CriPec® docetaxel. Furthermore, CriPec® docetaxel will be decorated with a PET tracer (89Zr), which enables oncologists to visualize CriPec® biodistribution in real-time. Tumour uptake will be correlated with therapeutic responses and result in parameters for future patient selection. This approach turns the drug into a personalized medicine whereby only those patients that exhibit enhanced tumour-targeting will be treated. This personalisation assures maximum efficacy in selected patients, avoids exposing patients to inappropriate drugs and adverse effects, and allows patients with limited tumour targeting to receive other more appropriate treatment. CT will use INTACT to close the gap from lab to market and facilitate a licensing deal for CriPec® docetaxel, projected to generate revenues exceeding >€100M in 2024. More importantly, INTACT will validate the CriPec® nanomedicine platform, boost product development for other diseases through licensing deals, and provide a growth of 10FTE by 2022. Success in INTACT will truly launch Cristal Therapeutics’ business.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INTACT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "INTACT" are provided by the European Opendata Portal: CORDIS opendata.